Human SCARB2-Mediated Entry and Endocytosis of EV71

Yi-Wen Lin1,2,9, Hsiang-Yin Lin1,9, Yueh-Liang Tsou1,3, Ebenezer Chitraper 1,8, Kuang-Nan Hsiao1, Hsiao-Yun Shao1, Chia-Chyi Liu1, Charles Sia1,4, Pele Chong1,4,*, Yen-Hung Chow1,*

1 National Institutes of Infectious Disease and Vaccinology, National Health Research Institutes, Taiwan, Republic of China, 2 Graduate Program of Biotechnology in Medicine, Institute of Molecular Medicine, National Tsing Hua University, Hsinchu, Taiwan, 3 Graduate School of Life Science, National Defense Medical Center, Taipei, Taiwan, 4 Graduate Institute of Immunology, China Medical University, Taichung, Taiwan

Abstract

Enterovirus (EV) 71 infection is known to cause hand-foot-and-mouth disease (HFMD) and in severe cases, induces neurological disorders culminating in fatality. An outbreak of EV71 in South East Asia in 1997 affected over 120,000 people and caused neurological disorders in a few individuals. The control of EV71 infection through public health interventions remains minimal and treatments are only symptomatic. Recently, human scavenger receptor class B, member 2 (SCARB2) has been reported to be a cellular receptor of EV71. We expressed human SCARB2 gene in NIH3T3 cells (3T3-SCARB2) to study the mechanisms of EV71 entry and infection. We demonstrated that human SCARB2 serves as a cellular receptor for EV71 entry. Disruption of expression of SCARB2 using siRNAs can interfere EV71 infection and subsequent inhibit the expression of viral capsid proteins in RD and 3T3-SCARB2 but not Vero cells. SiRNAs specific to clathrin or dynamin or chemical inhibitor of clathrin-mediated endocytosis were all capable of interfering with the entry of EV71 into 3T3-SCARB2 cells. On the other hand, caveolin specific siRNA or inhibitors of caveolae-mediated endocytosis had no effect, confirming that only clathrin-mediated pathway was involved in EV71 infection. Endocytosis of EV71 was also found to be pH-dependent requiring endosomal acidification and also required intact membrane cholesterol. In summary, the mechanism of EV71 entry through SCARB2 as the receptor for attachment, and its cellular entry is through a clathrin-mediated and pH-dependent endocytic pathway. This study on the receptor and endocytic mechanisms of EV71 infection is useful for the development of effective medications and prophylactic treatment against the enterovirus.

Citation: Lin Y-W, Lin H-Y, Tsou Y-L, Chitra E, Hsiao K-N, et al. (2012) Human SCARB2-Mediated Entry and Endocytosis of EV71. PLoS ONE 7(1): e30507. doi:10.1371/journal.pone.0030507

Editor: Lisa Ng Fong Poh, Agency for Science, Technology and Research - Singapore Immunology Network, Singapore

Received July 12, 2011; Accepted December 18, 2011; Published January 17, 2012

Copyright: © 2012 Lin et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: This work was supported by the National Health Research Institutes’ intramural grant (99A1-VCPP08-014) (www.nhri.org.tw) and a grant (99-2323-B-400-014) from the National Science Council (NSC) (http://web1.nsc.gov.tw) of Taiwan. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing Interests: The authors have declared that no competing interests exist.

* E-mail: pelechong@nhri.org.tw (PC); choeyenh@nhri.org.tw (Y-HC)

These authors contributed equally to this work.

† Current address: Division of Human Biology, School of Medical Sciences, International Medical University, Kuala Lumpur, Malaysia

Introduction

Enterovirus 71 (EV71), a positive single stranded RNA virus belonging to the family Picornaviridae is known to manifest hand-foot-and-mouth disease (HFMD) in young children, and can lead to the development of severe neurological diseases including aseptic meningitis, cerebellar encephalitis, and acute flaccid paralysis culminating in fatality in some patients especially children [1,2,3,4,5]. The first EV71 infection was recorded in California in 1969 [6], and then opened an outbreak in Bulgaria in 1975 resulted in 44 fatal cases [7], also reported 47 fatalities in Hungary in 1978 [8], 34 fatalities in Malaysia in 1997 [1,9], 78 fatalities in Taiwan in 1998 [10,11]. Following epidemics in Taiwan that caused 25 deaths in 2000, 26 deaths in 2001, and 14 deaths in 2008 [12,13,14], and more cases of EV71 infection are sporadically reported in many countries. Till now the treatment and control of EV71 infection are only symptomatic due to the lack of effective medications and unavailability of a prophylactic vaccine [15].

Two different membrane proteins, human P-selectin glycoprotein ligand-1 (PSGL-1; CD162) [16] and human scavenger receptor class B, member 2 (SCARB2) [17] have been identified as cellular receptors for EV71. PSGL-1 is a sialomucin membrane protein widely expressed in leukocytes that plays a role in early stages of inflammation [18,19,20]. SCARB2, also called lysosomal integral membrane protein 2 or CD36b like-2, has two transmembrane domains with the N and C termini located in the cytosol [21]. It is expressed in many tissues, participates in membrane transport and the reorganization of the endosomal/lysosomal compartment [22] and high density lipoprotein endocytosis (HDL) [23]. Based on their PSGL-1-binding capability, different EV71 isolates are classified into PSGL-1-dependent and PSGL-1-independent strains. SK-EV006 (genogroup B3), C7/Osaka (B4), KED005 (C1), 1095 (C2) and 75-Yamagata (C4) are PSGL-1-dependent strains. BrCr (genogroup A), Nagoya (B1), and 02363 (C1) are PSGL-1-independent isolates [16,24]. Some EV71 strains such as BrCr (A), Nagoya (B1), and Ishihara (C) have been reported to utilize SCARB2 as a receptor. Expression of human SCARB2 receptor in susceptible cell lines was found to facilitate these strains of EV71 and coxsackievirus A16 (CVA16) infection resulting in the development of cytopathic effects [17].

Viruses enter into host cells through endocytosis followed fusion of the viral envelope with the endosomal membrane facilitating...
delivery of the viral genome into the cytosol. Although the endocytic pathways used by some viruses, such as influenza virus [25], hepatitis C virus (HCV) [26], respiratory syncytia virus (RSV) [27,28], severe acute respiratory syndrome coronavirus (SARS-CoV) [29], vesicular stomatitis virus (VSV) [30,31], simian virus 40 (SV40) [32], Ebola virus [33], and echovirus I [34] have been determined. Viruses entering cells through clathrin- or caveolin-mediated endocytosis, as well as clathrin- and caveolin-independent pathways have been reported [35,36,37]. In clathrin-mediated endocytosis, virus-bound receptors are targeted to clathrin-coated pits (CCPs), which mature into clathrin-coated vesicles (CCVs) resulting in the internalization of viruses with their receptors. Caveolin-mediated endocytosis is also a well-characterized process, which involves the association of glycolipid rafts of plasma membrane with caveolins resulting in their internalization [37]. Dynamins, the large GTPase of molecular size 100 KDa are involved in the budding and scission of nascent vesicles from the parent membranes during clathrin-mediated endocytosis [38,39]. Several studies have identified the recruitment of dynamin to the neck of nascent CCVs prior to fission [40,41,42]. Additionally, dynamins have been implicated in the budding of caveolin, phagocytosis and vesicle cycling at the neuron-muscular junction [43]. Recent studies has mapped the encoding sequence at the region of amino acid 142 to 204 of human SCARB2 that is critical for EV71 binding and infection [44]. The clathrin-mediated endocytosis as the entry pathway for EV71 infection was identified [45]. However, the detail of receptor-mediated entry mechanism for EV71 has still needs more exploration.

Our investigation focuses on the entry mechanism of EV71 in SCARB2-expressing cells. We have infected the SCARB2-overexpressing NIH3T3 cells (3T3-SCARB2), RD, and Vero cells with EV71/E59 strain, a B4 sub-genotype isolated in Taiwan in 2002. Expression of SCARB2 had made the 3T3-SCARB2 and RD cells susceptible to EV71 infection, proving that SCARB2 is a functional receptor of EV71. Both viral infection and replication was well supported in 3T3-SCARB2 and RD cells, while SCARB2-independent EV71 susceptibility was observed in Vero cells. We demonstrates that EV71 entry into 3T3-SCARB2 is through clathrin-dependent endocytosis which was inhibited significantly by knocking down the clathrin or dynamin expression using specific siRNAs or by using inhibitors of clathrin-dependent endocytosis. Moreover, the examined endocytosis of EV71 is pH-dependent as it was inhibited by endosomal acidification inhibitors. Taken together, our results demonstrate that EV71 binds to SCARB2 and triggers a clathrin- and dynamin-dependent endocytosis for its entry.

**Materials and Methods**

**Cell culture**

African green monkey kidney (Vero) (ATCC No. CCL-81) and human rhabdomyosarcoma (RD) (ATCC No. CCL-136) cells were provided by the Taiwan Centers of Disease Control (Taiwan CDC); the original cell lines were obtained from the American Type Culture Collection (ATCC). A549 (ATCC No. CCL-185), a human lung adenocarcinoma lines, were purchased from ATCC. NIH3T3 mouse fibroblast cells (ATCC No. CRL-1658) were kindly obtained from Dr. Pele Chong, National Institutes of Infectious Disease and Vaccinology, National Health Research Institutes, Taiwan. The original NIH3T3 cell lines were purchased from ATCC. Vero cells were cultured in VP-SFM medium (GIBCO) supplemented with 5% fetal bovine serum (FBS) (Biological Industries), and 1% penicillin/streptomycin (P/S) (Biological Industries). NIH3T3, RD and A549 cells were grown and maintained in Dulbecco’s modified Eagle’s medium (Hyclone) plus 10% FBS, and 1% P/S. Cells were maintained in an incubator at 37°C and equilibrated with 5% CO2.

NIH3T3 cells at 80% confluency were transfected with pCMV-SCARB2 plasmid by cationic polymer-DNA transfection method. NIH3T3 cells were grown in a 12-well plate, and 0.5 µg of plasmid DNA pre-mixed with 1 µL of TurboFect transfection reagent (Fermentas) was added to 50 µL culture medium for each well and then cultured in the incubator for 24 hours. Stable cells overexpressing SCARB2 were selected in the presence of 800 µg/ ml of G418 (Sigma-Aldrich). Stable cell line 3T3-SCARB2 was established by expansion of a single cell originally cultured in 96-well plate in the presence of G418 after two weeks of culture.

**Plasmids and viruses**

Human SCARB2 gene sequence published recently [17] was codon-optimized and synthesized commercially by GENEART, Germany and inserted into pDNA3.1(+) vector (Invitrogen) containing enhancer/promoter of cytomegaviruses (CMV), simian virus 40 (SV40) poly A tail, and neomycin-resistant gene, at EcoRI/BamHI cloning site to obtain pCMV-SCARB2 plasmid. EV71/E59 strain, a B4 sub-strain isolated in Taiwan in 2002 by Taiwan CDC was propagated in Vero or 3T3-SCARB2 cells. Briefly, 2x10⁶ cells cultured in a 10-cm dish were infected with live EV71/E59 virus at a MOI (multiplicities of infection) of 1x10⁻³. The culture supernatant was harvested 5 days after infection and passed through a 0.45 µm filter (Sartorius) to remove the cell debris. The culture supernatant was tested in a standard virus plaque forming assay to determine its infectious viral content. It was aliquoted and stored at −80°C as the viral stock.

Recombinant lentivirus-eGFP which carries green fluorescence protein (GFP) was obtained from the National RNAi Core Lab in Genomics Research Center of Academia Sinica, Taiwan.

**Flow cytometry**

1x10⁶ NIH3T3, 3T3-SCARB2, Vero, and RD cells were harvested from trypsin-free dissociation buffer (GIBCO) treated culture dishes and spun down to remove the supernatant. Cells were washed once with 1xPBS (pH = 7.4) and then fixed with 70% ice-cold methanol in PBS or non-permealization/fixation solution (0.5% paraformaldehyde in PBS) for overnight. The cells were washed, and 1 mL of 1 to 1000 dilution of biotinylated anti-SCARB2 antibody (R&D) was added and incubated at 4°C for 1 hour. After incubation, the cells were washed and stained with 1:2000 diluted fluorescence isothiocyanate (FITC)-conjugated streptavidin (Bioreagent) for 30 minutes. SCARB2-expressing cells were detected using FACScan flow cytometer and analyzed using the CellQuest software (Becton Dickinson Immucytometry System). 3T3-SCARB2 cells stained only with FITC-streptavidin were used as conjugate control for deducting the background.

**EV71- specific enzyme-linked immunosorbent assays (ELISA)**

Cells cultured at a density of 10⁴ per well in 96-well plate were incubated with varied MOIs of EV71 in 100 µL of serum-free DMEM medium for one hour at 37°C. After one hour of infection, the cells were washed three times with 1xPBS (pH = 7.2), and cultured in 1serum-free DMEM for another 24 hours. Cells were washed again with 1xPBS (pH = 7.2) and then fixed with 100 µL of 100% methanol for 30 minutes at room temperature, and then 250 µL of 5% skim milk-PBS was added to each well to block the non-specific binding of the detection
antibodies. 100 μL of the antibody solution (containing 0.1 μL of the E1 monoclonal antibody, produced from a hybridoma line generated from EV71/E59-immunized BALB/c mouse at National Health Research Institutes, vaccine Center, Taiwan) prepared in PBS containing 5% skim milk was added to each test well to detect the viral capsid proteins. After 2 hours incubation at room temperature, the plate was washed four times by pipetting 250 μL of 1x PBS into the individual wells. 100 μL of HRP-conjugated anti-mouse IgG (Jackson ImmunoResearch) diluted at 1 in 5,000 in assay buffer was then added to each well and incubated for 1 hour at room temperature before washing the plate four times with 1x PBS. 70 μL of TMB peroxidase substrate (SureBlue[3M], KPL) was added to the individual assay well and allowed to react for 30 min at room temperature. The reaction was stopped by adding 70 μL 2N H2SO4 to each well and the absorbance was recorded at OD 450 nm using an ELISA reader (Spectra Max M2 model, Molecular Devices, USA).

### Antibodies and western blot

Anti-VP2 specific monoclonal antibody, MAB979, was obtained from Millipore-Chemicon International. Anti-SCARB2 antibody was purchased from R&D. Antibodies specific to clathrin and dynamin were purchased from Abcam and Santa Cruz Biotechnology, Inc., respectively. Anti-caveolin-1 antibody was purchased from Cell signaling. De novo synthesis of VP1 and VP2 in EV71-infected cells and expression of SCARB2 in the cells were assessed by Western blot.

Cell lysates were prepared by treatment of 1–2×10^6 cells in 100 μL of ice-cold lysis buffer (0.5% sodium deoxycholate, 0.1% sodium dodecyl sulfate (SDS), 0.5% NP-40, 50 mM TRIS, 150 mM NaCl) with the addition of a protease inhibitors cocktail (Roche) and 1 mM PMSF (Sigma-Aldrich). Lysates were then centrifuged for 20 min at 10,000 rpm, at 4°C to sediment cell debris. Cell lysate was subjected to SDS-polyacrylamide gel electrophoresis (SDS-PAGE) (Amersham Biosciences). This entailed loading 10 μg of the cell lysate mixed with loading dye per well of a 10% SDS-PAGE. Following electrophoresis at 100 V for 90 minutes in 1X Tris-glycine SDS-running buffer, the resolved proteins were transferred onto a nitrocellulose membrane (Hybond-ECL, Amersham Biosciences). Protein-containing membrane was soaked in 5% skim milk in PBS, pH 7.4 for 30 min at room temperature, then washed three times with 10 mL of assay buffer [PBS, pH 7.4 containing 0.05% Tween 20]. The membrane was incubated with 1: 5000 diluted MAB979, or 1: 2000 diluted anti-SCARB2 antibody, for 14–16 hours at 4°C, and subsequently washed 5 times with 15 mL of assay buffer followed by incubation with horseradish peroxidase (HRP)-conjugated donkey anti-mouse secondary antibody (Jackson Immunoresearch) at a dilution of 1 in 5,000 (for MAB979), or HRP-conjugated anti-goat secondary antibody (Jackson Immunoresearch) at a dilution of 1:5,000 (for anti-SCARB2 antibody). After 1 hour incubation at room temperature, the membrane was washed 5 times with the assay buffer, and 1 mL of SuperSignal West Pico chemiluminescent substrate (Pierce) was then layered onto the membrane. The reaction was detected by exposing the membrane to an X-ray film (Kodak) at 30 sec, 1, 3, and 5 minutes intervals. When necessary membranes were stripped with a restoring membrane to an X-ray film (Kodak) at 30 sec, 1, 3, and 5 minutes intervals. When necessary membranes were stripped with restoring solution (containing 0.1 μL of TurboFect siRNA transfection Reagent (Fermentas) was added per well of a 12-well plate and incubated at 37°C for 1 hour before washing the plate three times with the assay buffer. The plates were blotted dry on paper towel, 100 μL of TMB substrate (KPL) was added to the individual assay wells and the plates were incubated in dark for 30 minutes. The plaques representing cells infected by EV71 virus were seen as black spots in each test well and their number was taken for calculating plaque-forming units (pfu) to represent the virus infectivity.

### Down-regulation of cellular gene expression by siRNA

3T3-SCARB2 cells at 80% confluence were transfected with oligonucleotides of siRNA specific to target gene or the control siRNA by liposome-oligonucleotide transfection method. Briefly, 50 μL culture medium containing 50 or 100 pmol of siRNA premixed with 1 μL of TurboFect siRNA transfection Reagent (Fermentas) was added per well of a 12-well plate and incubated at 37°C for 24 or 48 hours in an incubator. After incubation, the cells were infected with EV71 (MOI = 0.04) in serum-free culture medium followed by 1 hour incubation at 37°C before washing three times with serum-free culture medium. After 24 or 48 hours of incubation, cell lysates were prepared for western blot. SCARB2 siRNA (sc-41546) was purchased from Santa Cruz Biotechnology, Inc. SiRNAs specific to mouse clathrin light chain B (Gene bank Accession No. M20469) (One-TARGET plus SMART pool, Cat. No. L-044978-01-0005), mouse dynamin 2 (Gene bank Accession No. L36983) (One-TARGET plus SMART pool, Cat. No. L-044919-02-0005), mouse caveolin-1 siRNA (Invitrogen), and negative control siRNA were purchased from Invitrogen. The blots were quantified using Image –Pro Plus 6.0 software.

### Inhibition of endocytosis and endosomal acidification

1×10^5 3T3-SCARB2 cells seeded in a 12-well plate one day prior to the experiments were treated with various concentrations of inhibitor for one hour and then infected with EV71 (MOI = 0.04) in
serum-free culture medium for 1 hour at 37°C in the presence of inhibitor. The cells were washed three times with serum-containing culture medium and after additional 24 hours of culturing in the presence of the inhibitor, the cells were harvested and lysed for immunoblotting using MAB979 antibody. For lentivirus-eGFP infection, 4×10^5 A549 cells were seeded in a 12-well plate one day prior to the treatment with genistein (dissolved in 0.1% DMSO) or vehicle alone for one hour and then infected with lentivirus-eGFP (MOI = 0.1). After infection, cells were washed and then following cell culture until 72 hours. Without infection with lentivirus-eGFP of A549 cells were included as GFP negative control. The same field of fluorescent and visible pictures was taken under the UV-fluorescent microscopy (Olympus DP70) and GFP-positive cells were counted. For the assay of the internalization of cholera toxin subunit B (CT-B), 1×10^5 3T3-SCARB2 cells were grew on a coverslip one day and then washed to remove any serum prior to the treatment with filipin (dissolved in 0.1% DMSO vehicle) or vehicle alone for one hour at 37°C. All subsequent incubations contained the inhibitors. Cells were cooled to 15°C and then incubated with 5 μg/mL alexa fluor 594 CT-B conjugate (dissolved in 0.1% DMSO) (Invitrogen). After 30 minutes incubation, cells were washed and either fixed immediately. The cells were fixed with 4% paraformaldehyde for 20 minutes at 37°C and washed three times in PBS. The slides were then mounted with a coverslip and the cells observed in the same field of fluorescent and visible pictures was taken by the confocal microscopy (Leica TCS SP5 II).

Depletion of cholesterol from the plasma membrane using MβCD was done as described [46]. Cells were treated with serial dilutions of MβCD for 30 minutes prior to the infection with EV71 as described above.

The following compounds used as inhibitors were purchased from Sigma-Aldrich, St Louis, MO, USA: genistein, filipin, methyl β-cyclodextrin (MβCD), chloroquine, and ammonium chloride (NH₄Cl), chlorpromazine (CPZ) was obtained from Alexis Biochemicals.

Results
Expression of SCARB2 in transfected NIH3T3 cells
To explore the role of SCARB2 while EV71 virus entry, EV71 virus was cultivated in RD and Vero cells that already express SCARB2 and in NIH3T3 cells engineered to express human SCARB2. Human SCARB2 gene was cloned into pCMV expression vector under the CMV promoter to obtain pCMV-SCARB2 plasmid. NIH3T3 cells which are naturally not susceptible to EV71 were transfected with pCMV-SCARB2 plasmid and selected with G418 to establish a stable SCARB2-expressing cell line, 3T3-SCARB2.

The expression levels of SCARB2 in Vero, RD and 3T3-SCARB2 cells were examined by Western blotting using a polyclonal antibody specifically against the cytosolic domain of SCARB2. The expressed SCARB2 protein was identified to have a molecular weight of 80 KDa and the determined expression level was very high in 3T3-SCARB2, moderate in RD cells, but very little in Vero cells. No SCARB2 was detected in the cell lysate from NIH3T3 cells (Fig. 1A). The following treatment of cells with

![Figure 1. Expression of SCARB2 in RD, Vero, NIH3T3, and 3T3-SCARB2 cells.](https://doi.org/10.1371/journal.pone.0030507.g001)
permealization/fixation solution and then analyzed by flow cytometry also confirmed the cytosolic expression of SCARB2 in 3T3-SCARB2, RD, and Vero cells (Fig. 1B). However, flow analysis of NIH3T3, 3T3-SCARB2, RD, and Vero cells that were treated with a non-permealization/fixation solution to maintain the intact membrane structure could not detect SCARB2 on the surface (data not shown). It is probably due to SCARB2 dynamically cycling between the endosomal/lysosomal compartments and plasma membrane while transports cellular proteins from outside of cells into the cells [23]. Moreover, another identified EV71 receptor, PSGL-1, usually expressed in leukocytes [16]. Our RT-PCR analysis also revealed that NIH3T3, Vero and RD cells did not express PSGL-1 (data not shown).

SCARB2 expression in 3T3-SCARB2 facilitates EV71 infection

To confirm that SCARB2 expression per se facilitates infection with EV71 virus, 3T3-SCARB2, RD, Vero and NIH3T3 cells were inoculated with two concentrations of EV71 virus and examined for viral infection. Cytopathic effects were observed in 3T3-SCARB2, RD, and Vero cells. The expression of EV71 capsid proteins namely VP2 and VP4 in the infected cells was demonstrated by western blot using a VP2-specific monoclonal antibody MAB979 which has been identified [47]. Previous studies showed that multiple capsid proteins of VP0 (38 KDa, a precursor product of VP2+VP4), VP1 (36 KDa), VP2 (28 KDa), VP3 (25 KDa) and VP4 (8 KDa) were detected in the EV71-infected cells [48,49,50]. Corroborating these findings, we observed that 3T3-SCARB2, Vero and RD cells infected with EV71 were able to express capsid proteins with molecular weights in the range of 38 KDa (for VP0), and 28 KDa (for VP2), and 25 KDa (for VP3) (Fig. 2A). In NIH3T3 cells, neither the cytopathic effect nor the expression of viral capsid proteins was seen confirming that these cells were unsusceptible to EV71 infection and that SCARB2 expression had converted it into a susceptible cell line. The expression level of viral capsid protein was found to synchronize with the increase in multiplicity of infection (MOI) of EV71 from 0.04 to 1. The level of expression of viral capsid protein was the highest in 3T3-SCARB2 cells, moderate in RD cells and the lowest in Vero cells, in which were corresponding to the individual

Figure 2. Susceptibility of SCARB2-expressing cells infected with EV71. (A) Four different cells, NIH3T3, 3T3-SCARB2, RD, and Vero cells, were infected with two different MOI of EV71 and then cultured for 48 hours. After incubation, cell lysates were prepared for western blot using anti-capssid MAB979 antibody. (B) Immune plaque forming assay was performed in four different cells infected with 10-fold serial diluted 10^8 pfu/ml stocks of EV71 as described in the Materials and Methods. The immuno-stained plaques were counted and photography was taken. (C) NIH3T3 or SCARB2-expressing NIH3T3, RD, and Vero cells cultured in 96-well plate were inoculated with various MOI of EV71 for one hour at room temperature. After incubation, cells were washed three times with PBS and then cultured for another 24 hours before fixed by methanol. EV71 capsid protein in the cells was detected by ELISA assay as described in the materials and methods.

doi:10.1371/journal.pone.0030507.g002
expression levels of SCARB2. This finding confirms a correlation between SCARB2 expression and susceptibility to EV71. The correlationship was further investigated by infecting NIH3T3, 3T3-SCARB2, Vero, and RD cells with serial dilutions (10^{-3} to 10^{-8} pfu) of EV71 followed by determination of plaque formation by immuno-plaque assay. We observed that 3T3-SCARB2 with the highest level of SCARB2 expression (Fig. 1A) was susceptible to ~1x10^{-8} dilution of EV71 whereas RD cells with moderate expression were susceptible to ~5x10^{-7} dilution of EV71. Interestingly, Vero cells with the lowest level of SCARB2 expression acquired ~3x10^{-7} dilution of EV71 to get infected (Fig. 2B), and as expected, no plaques were formed in NIH3T3 cells, which were unsusceptible. Moreover, ELISA assay to compare the cell susceptibility for EV71 infection was also performed (Fig. 2C). 3T3-SCARB2 cells expressed the highest EV71 capsid protein was detected in a dose-dependent manner. No EV71 capsid protein was detected in NIH3T3 cells which do not express SCARB2. RD cells showed the moderate expressed EV71 virus. Nevertheless, Vero cells could be efficiently infected with EV71 virus (Fig. 2C), in spite of their low levels of SCARB2 (Fig. 1A). By comparison of the order of the susceptibility to EV71 infection (3T3-SCARB2>R>RD) with the level of SCARB2 expression (3T3-SCARB2>R>RD), it is possible that Vero cells possess other binding proteins to support EV71 infection.

Our results not only confirm the role of SCARB2 as a receptor for EV71 infection but also demonstrate that the degree of susceptibility to EV71 depends on the expression levels of SCARB2 in the cells.

Interaction of EV71 capsid protein with SCARB2 receptor

To examine whether SCARB2 interacts with EV71 in the cells, co-immunoprecipitation of EV71 virions with SCARB2 in the 3T3-SCARB2 protein was performed. Cell extracts prepared from 3T3-SCARB2 or NIH3T3 cell line was mixed with excess EV71 viral particles to allow the virus to associate with SCARB2. The complex was then immunoprecipitated using protein G-conjugated anti-SCARB2 antibody. Western blotting of precipitates with anti-EV71 MAB979 demonstrated that EV71 virions were precipitated from 3T3-SCARB2 cells but not from control NIH3T3 cells (the top panel of Fig. 3), compared to immunoblotting of lysate-viruses mixtures from both cell lines that corresponding EV71 capsid protein were observed. SCARB2 was detected in co-immunoprecipitates and lysate-viruses mixtures from 3T3-SCARB2 but not NIH3T3 cells while the same membrane was stripped and then re-blotted with anti-SCARB2 antibody (the bottom panel of Fig. 3), confirming that SCARB2 interacting with EV71 capsid protein could be pulled down from 3T3-SCARB2 but not from NIH3T3 cells. This result demonstrates that SCARB2 does associate with EV71 and therefore acts as a cellular receptor for EV71 infection.

Knocking down SCARB2 inhibits EV71 infection

To further prove that SCARB2 is the key protein supporting EV71 infection, endogenous SCARB2 expressed in RD and Vero cells was knocked down using SCARB2-specific siRNA. Cells were transfected with SCARB2 siRNA followed by 24 or 48 hours of incubation (t24 or t48), and subsequently infected with EV71 (MOI = 0.04) for 24 or 48 hours (i24 or i48). SCARB2 expression level in siRNA-transfected cells was monitored at 24 or 48 hours after transfection by Western blot using anti-SCARB2 antibody. It was found that expression of SCARB2 was reduced by almost 100% in RD cells transfected with 100 pmoles of SCARB2 siRNA, compared to control siRNA-transfected cells (the top panel of Fig. 4A). However, the expression of EV71 capsid protein in infected RD cells was completely inhibited upon transfection with 100 pmoles of SCARB2 siRNA, while the capsid protein expression was significantly reduced in cells transfected with 50
pmoles of siRNA (the bottom panel of Fig. 4A). Expression of capsid protein was not affected in mock-transfected cells.

A similar experiment performed in Vero cells revealed that transfection with 50 or 100 pmoles of SCARB2 siRNA had no inhibitory effect on the synthesis of EV71 capsid proteins (the bottom panel of Fig. 4B), even though the ~100% of SCARB2 expression was inhibited by siRNA transfection (the top panel of Fig. 4B). These findings suggest that SCARB2 is the major receptor for EV71 infection in RD cells but not in Vero cells, where other unidentified proteins function as receptor for EV71 infection.

**Cellular entry of EV71 is dependent on clathrin and dynamin**

SCARB2 is known to induce clathrin-, but not caveola-, mediated endocytosis in the internalization of HCV into target cells [51], and in HDL endocytosis [23]. In an attempt to unravel the mechanism of EV71 entry into 3T3-SCARB2 cells, several compounds known to inhibit clathrin- and caveolin-mediated endocytosis were used to annotate the pathway involved in EV71 entry. Chlorpromazine (CPZ) is a cationic amphiphilic reagent that inhibits the assembly of clathrin-coated pits at the plasma membrane [52,53]. It has been used to test out clathrin-mediated endocytosis in many viruses such as influenza virus [25], HCV [26], SARS-CoV [29], VSV [30], and RSV [27]. 3T3-SCARB2 cells pretreated with various concentrations of CPZ showed a dose-dependent reduction in the synthesis of de novo capsid proteins following EV71 infection. Significant inhibition of capsid protein synthesis was observed at CPZ concentration of 5.0 μg/mL (Fig. 5A). These findings suggest that clathrin-mediated endocytosis played a crucial role in EV71 entry.

To further examine EV71 entry is clathrin-dependent course, endogenous clathrin expression in 3T3-SCARB2 cells was knocked down using clathrin light chain B (CLTB)-specific siRNA. Downregulation of cellular 30 KDa of CLTB expression was observed at 24 and 48 hours after transfection with 100 pmoles of clathrin-specific siRNA, compared to mock-transfected cells (the top panel of Fig. 5B). It was observed that 100 pmoles of clathrin

---

**Figure 4. Infection of EV71 in RD cells but not Vero cells is SCARB2-dependent.** (A) RD cells, and (B) Vero cells were transfected with two different amount of SCARB2 siRNA and then incubated for 24 or 48 hours before MOI = 0.04 of EV71 infection. Lysates prepared at 24 or 48 hours after siRNA transfection were subjected to western blot using anti-SCARB2 antibody (the top panel). Cell lysates were extracted at 24 or 48 hours after EV71 infection and subjected to detect the synthetic viral capsid protein by western blot using MAB979 antibody (the lower panel). The internal control of cellular β-actin was detected by blotting the same membrane with monoclonal anti-β-actin antibody. Corresponding changes in SCARB2 protein levels compared to the expression levels in 48 hours transfection of the cells with 100 pmoles control siRNA (Mock) as 1.0 were quantified using Image-Pro Plus 6.0 software. Data represent one of two independent experiments.

doi:10.1371/journal.pone.0030507.g004
siRNA was sufficient to block EV71 capsid protein synthesis at 48 h post transfection (the bottom panel of Fig. 5B). These results prove that EV71 entry into 3T3-SCARB2 cells is facilitated by clathrin-mediated endocytosis.

Dynamin family proteins have been reported to tabulate and save membrane-coated vesicles and plays a role in membrane fission that associated with clathrin-dependent and clathrin-independent endocytic processes [38,39,54]. The expression of dominant-negative dynamin mutants (dynaminK44A) has been shown to block the formation of clathrin-coated pits and vesicles [55,56]. These observations have prompted us to investigate whether dynamin may also play a role in EV71 entry mechanism. Dynamin-2 expression could be inhibited after 24 and 48 hours of 3T3-SCARB2 cells transfected with 200 pmoles of dynamin-2-specific siRNA as judged by the detection of dynamin (100 KDa) in the immunoblot assay (the top panel of Fig. 6). Dynamin-2-specific siRNA pretreatment of 3T3-SCARB2 cells affected the EV71 virus replication in a dose-dependent manner. The production of viral capsid proteins was completely inhibited in cells transfected with 200 pmoles of dynamin-2 siRNA, whereas only moderate inhibition of viral capsid protein was seen in cells treated with 100 pmoles of dynamin-2 siRNA (Fig. 6). Our observations confirm that dynamin plays a crucial role in EV71 endocytosis through clathrin-mediated pathway.

**EV71 entry is independent of caveolae**

Besides clathrin-dependent endocytosis, other alternate mechanisms have been described to be involved in viral entry. Caveolae have been implicated in the uptake of viruses such as SV40, polyomavirus, ebola virus, echovirus I, lentivirus, and others [28,31,32,33,34,57]. In the study of caveolae-mediated virus entry, genistein, a tyrosine kinase inhibitor, can interrupt caveolae-mediated endocytosis [58,59,60], and filipin, a cholesterol-binding agent, is capable of disrupting the caveolar structure and function [61,62,63], were subjected to test the ability in the inhibition of EV71 infection using a two-fold of the maximally effective dose that has been reported [58,61,62]. 3T3-SCARB2 cells were treated with genistein prior to the infection with EV71. Maximal dose of 20 μg/mL genistein had no inhibitory effect on the endocytosis of EV71 in infected 3T3-SCARB2 cells (Fig. 7A), as
compared to the control group of A549 cells which pre-treated with the same dose of genistein was significantly resistant to lentivirus-eGFP infection (Fig. 7B). Similar result was observed in 3T3-SCARB2 cells pre-treated with the maximal dose of 2 μg/mL filipin that had no inhibition in EV71 entry into 3T3-SCARB2 cells (Fig. 8A). It was in contrast to the significant suppression of the uptake of alexa fluor 594 cholera toxin subunit B (CT-B) conjugate in 3T3-SCARB2 cells by the same dose of filipin (Fig. 8B). The mechanism of cholera toxin internalization through caveolae endocytosis has been confirmed [62]. Caveolin riched in NIH3T3 cells was known [64]. We further knocked down the endogenous caveolin-1 (CAV-1) by specific siRNA. Caveolin expression could be inhibited after 24 and 48 hours of 3T3-SCARB2 cells transfected with 100 pmoles of CAV-1 siRNA as judged by immunoblot of the caveolin (22 KDa) (the top panel of Fig. 8C). However, 3T3-SCARB2 cells pre-treated with CAV-1 siRNA did not resist from EV71 infection (Fig. 8C). These results show clearly that EV71 entry using SCARB2 receptor is through clathrin- but not caveolae-dependent endocytosis.

EV71 endocytosis is dependent on endosomal pH and intact membrane cholesterol

Generally, enveloped viruses attach to the host cells through bind to the surface of host and then enter either at acidic pH or neutral pH. Acidic pH-dependent group includes VSV, influenza A virus, adenovirus and rubella virus [65]. Some viruses like RSV, SV40, measles virus, herpes simplex virus I, vaccinia virus and HIV-1 are insensitive to lysosomotropic agents [27,65,66,67] which are able to block endosomal acidification. For most viruses using clathrin-mediated endocytosis, transition from early-to-late stage endosome is pH-dependent [65]. After endocytosis, viruses containing early endosomes are configured to form acidic (pH 6.0 to 6.5) vesicles and become progressively more acidic as they mature to form late endosomes (pH 5.5 to 6.0). Progressive acidification of endosomes is required for the internalized viruses to establish their infection [65,68]. Specific compounds like NH<sub>4</sub>Cl [27,60] and chloroquine [26,27,60] are capable of inhibiting endosomal acidification and therefore employed to verify whether this phenomenon is
consequential for EV71 infection. 3T3-SCARB2 cells were treated with varied concentrations of NH4Cl or chloroquine prior to EV71 infection. It was observed that NH4Cl was able to inhibit EV71 capsid protein synthesis at concentration as low as 5 mM, while chloroquine showed a dose-dependent inhibition at the concentration of 5 μM with the maximal effect seen at 80 μM compared to untreated cells (Fig. 9A). These observations confirm that endocytosis of EV71 is pH dependent.

Cholesterol is required for receptor-mediated endocytosis of viruses via CCPs [69] and is essential for the structure and function of invaginated caveolae and caveolae-dependent endocytosis [70,71,72]. Both clathrin- and caveolae-mediated endocytosis require intact membrane cholesterol and are perturbed by methyl β-cyclodextrin (MβCD), an agent that removes cholesterol from the plasma membrane [73]. Pretreatment of 3T3-SCARB2 cells with various concentrations of MβCD prior to infection with EV71 revealed that MβCD was capable of inhibiting capsid protein synthesis in a dose-dependent manner (Fig. 9B). Viability of 3T3-SCARB2 cells was almost 100% at MβCD concentration of 4 mM or less, but cytotoxicity was observed at MβCD concentration of 8 mM (data not shown). Our results indicate that intact cell membrane cholesterol is essential for EV71 entry by clathrin-mediated endocytosis.

Our observations demonstrate that the route of internalization of EV71 particles in SCARB2-expressing cells involves clathrin, dynamin and is dependent on endosomal acidification and membrane cholesterol level.

Discussion

Productive infection of target cells by viruses requires entry pathways that allow viral components to be introduced into the cytoplasm for subsequent processes such as uncoating, gene expression, and replication. Previous studies with EV71 indicate that SCARB2 [17] and PSGL-1 [16] serve as cellular receptors for EV71 infection. Although endogenous mouse SCARB2 expressed by NIH3T3 cells has 85.8% homology to human SCARB2, it seems not to participate in the acute infection of NIH3T3 cells with EV71. Only 3T3-SCARB2 cells that overexpress human SCARB2 were highly susceptible to EV71, confirming that the expressed human SCARB2 serves as a receptor conferring susceptibility to EV71 infection. We have also observed that NIH3T3 cells cultured with EV71 for a long time (>5 days), showed some non-specific infection and replication of the virus, as indicated by the cytopathic effect and plaque formation (data not shown). This might be due to either mouse SCARB2 or some other cell surface protein functioning as a receptor for EV71, albeit with very low specificity. Mouse SCARB2 is a poor receptor for EV71 infection of mouse cells was also confirmed by Yamayoshi et al. [74]. In addition, Vero cells that are used as hosts for EV71...
infection and production [16,75] have marginal expression of SCARB2 but no expression of PSGL-1 confirming earlier observation [16]. It is possible that the apparently low expression of SCARB2 in Vero cells might be due to low affinity of the experimental used anti-SCARB2 polyclonal antibody towards green monkey SCARB2. Additionally, siRNA specific to SCARB2 could not inhibit EV71 infection in Vero cells even though the expression level of SCARB2 was impaired (Fig. 5), indicating that in these cells some other protein functions as a receptor for EV71 entry.

The interaction between SCARB2 receptor and EV71 capsid protein in 3T3-SCARB2 cells infected with EV71 has been clearly demonstrated by co-immunoprecipitation. In addition to ensure the role of SCARB2 as a receptor for EV71, our study also reveals that EV71 enters cells through clathrin- and dynamin-dependent endocytosis with progressive acidification of the endosomes. Similar pathways have been reported to be employed by other viruses. Polio virus uses CD155, a member of the immunoglobulin superfamily as a receptor to infect host cells [76,77,78] and enters the cells independent of clathrin and endosomal acidification [79]. RSV enters the cells through clathrin-mediated endocytosis at neutral pH [27,80]. Influenza virus enters target cells by both clathrin-dependent and -independent pathways of endocytosis [81,82].

It has been reported that upon endocytosis, the native viral particles containing the genomic viral RNA form subviral “A-particles” sedimenting at 13S, which then undergo a conformational change to create subviral “B-particles” that sediment at 80S induced by the low pH (≤5.6) at the endocytic carrier vesicles and late endosomes. Release of viral RNA from the protein shell of “B-particles” facilitates viral replication [55,83,84]. This antigenic conversion mediated by low pH is decreased in potassium-depleted cells [55]. Therefore, the resulting acidification of the endosomal environment would have enhanced the conversion of
EV71 "B-particles" to release the viral RNA resulting in enhanced expression of viral capsid proteins in the endosomal stage of EV71 infection.

In this study we confirm the role of SCARB2 as a receptor for EV71 and determine its internalization pathway to involve clathrin, dynamin and progressive acidification of endosomes. Our study paves way for understanding EV71 infectious pathway in human SCARB2 expressing cells and therefore is of consequence in planning prophylactic as well as therapeutic approaches to control EV71 infection.

**Author Contributions**

Conceived and designed the experiments: Y-HC. Performed the experiments: Y-WL H-YL Y-LT K-NH H-YS. Analyzed the data: PC EC CS. Contributed reagents/materials/analysis tools: C-CL. Wrote the paper: Y-HC. Edition of manuscript: PC EC GS.

**References**

1. AbuBakar S, Chee HY, Al-Kobaisi MF, Xiaoshan J, Chua KB, et al. (1999) Identification of enterovirus 71 isolates from an outbreak of hand, foot and mouth disease (HFMD) with fatal cases of encephalomyelitis in Malaysia. Virus Res 61: 1–9.

2. Alexander JP, Jr., Baden L, Pallansch MA, Anderson LJ (1994) Enterovirus 71 infections and neurologic disease–United States, 1977–1991. J Infect Dis 169: 905–908.

3. Chang LY, Huang YC, Lin TY (1998) Fulminant neurogenic pulmonary oedema and hand, foot, and mouth disease. Lancet 352: 367–368.

4. Chumakov M, Voroshilova M, Shindarov I, Lavrova I, Gracheva L, et al. (1979) Enterovirus 71 isolated from cases of epidemic poliomyelitis-like disease in Bulgaria. Arch Virol 68: 329–340.

5. McMinn PC (2003) Enterovirus 71 in the Asia-Pacific region: An emerging cause of acute neurological disease in young children. Neurological journal of Southeast Asia 8: 57–63.

6. Schmidt NJ, Lennette EH, Ho HH (1974) An apparently new enterovirus isolated from patients with disease of the central nervous system. J Infect Dis 129: 304–309.

7. Melnick JL, Schmidt NJ, Mirkowski RR, Chumakov MP, Lavrova IK, et al. (1980) Identification of Bulgarian strain 258 of enterovirus 71. J virol 12: 297–302.

8. Nagy G, Takatsy S, Kukan E, Mihaly I, Domok I (1980) Identification of enterovirus type 71 infections: experiences gained during an epidemic of acute CNS diseases in Hungary in 1978. Arch Virol 71: 217–227.

9. Lum LG, Wong KT, Lunn SK, Chua KB, Goh AY (1998) Neurogenic pulmonary oedema and enterovirus 71 encephalomyelitis. Lancet 352: 1391.

10. Wu TN, Tsai SF, Li SF, Lee TF, Huang TM, et al. (1999) Sentinel surveillance for enterovirus 71, Taiwan, 1998. Emerg Infect Dis 5: 450–460.

11. Ho M, Chen ER, Hsu KH, Tsu SJ, Chen KT, et al. (1999) An epidemic of enterovirus 71 infection in Taiwan. Taiwan Enterovirus Epidemic Working Group. N Engl J Med 341: 929–935.

12. Lee MS, Chang LY (2010) Development of enterovirus 71 vaccines. Expert Rev Vaccines 9: 149–156.

13. Lin KH, Hwang KP, Ke GM, Wang CF, Ke LY, et al. (2006) Evolution of EV71 genogroup in Taiwan from 1998 to 2005: an emerging of subgenogroup C4 of EV71. J Med Virol 78: 254–262.

14. Lu CH, Huang SW, Lai YL, Lin CP, Shih CH, et al. (2008) On the relationship between the protein structure and protein dynamics. Proteins 72: 625–634.

15. Qin J (2006) Enterovirus 71 infection: a new threat to global public health? Lancet Neurol 7: 868–869.

16. Ninomiya Y, Shimozuma T, Tano Y, Miyamura T, Wakita T, et al. (2009) Human Pselectin glycoprotein ligand-1 is a functional receptor for enterovirus 71. Nat Med 15: 794–797.

17. Yamayoshi S, Yamashita Y, Li J, Hanagata N, Minowa T, et al. (2009) Scavenger receptor B2 is a cellular receptor for enterovirus 71. Nat Med 15: 790–801.

18. Lassik Z, Jansen PJ, Cummings RD, Tedder TF, McEver RP, et al. (1996) P-selectin glycoprotein ligand-1 is broadly expressed in cells of myeloid, lymphoid, and dendritic lineage and in some nonhematopoietic cells. Blood 88: 3010–3021.

19. Sako D, Chang XJ, Barone KM, Vachino G, White HM, et al. (1993) Expression cloning of a functional glycoprotein ligand for P-selectin. Cell 75: 1179–1186.

20. Somers WS, Tang J, Shaw GD, Cambrelius RT (2000) Insights into the molecular basis of leucocyte tethering and rolling revealed by structures of P- and E-selectin bound to SLX and PSGL-1. Cell 103: 467–478.

21. Eskelinen EL, Tanaka Y, Saftig P (2003) At the acidic edge: emerging functions for lysosomal membrane proteins. Trends Cell Biol 13: 137–145.

22. Kurumita T, Eskelinen EL, Fujita H, Saftig P, Himeno M, et al. (2002) A role for the lysosomal membrane protein LGP85 in the biogenesis and maintenance of endosomal and lysosomal morphology. J Cell Sci 115: 4117–4131.

23. Eckhardt ER, Cai L, Shetty S, Zhao Z, Szanto A, et al. (2006) High density lipoprotein endocytosis by scavenger receptor SR-BII is clathrin-dependent and requires a carboxyl-terminal dileucine motif. J Biol Chem 281: 4348–4355.

24. McMinn PC (2002) An overview of the evolution of enterovirus 71 and its clinical and public health significance. FEMS Microbiol Rev 26: 91–107.
25. Sieczkowski SB, Whitaker GR (2003) Differential requirements of Rab5 and Rab7 for endocytosis of influenza and other enveloped viruses. Traffic 4: 333–343.
26. Blanchard E, Belouzard S, Goursat L, Watake T, Dabousson J, et al. (2006) Hepatitis C virus entry depends on clathrin-mediated endocytosis. J Virol 80: 6964–6972.
27. Kolokoltsov AA, Deniger D, Fleming EH, Roberts NJ, Jr., Karpilow JM, et al. (2007) Small interfering RNA profiling reveals key role of clathrin-mediated endocytosis and early endosome formation for infection by respiratory syncytial virus. J Virol 81: 7786–7800.
28. Sun N, Yau VK, Briggs BJ, Whitaker GR (2005) Role of clathrin-mediated endocytosis during vesicular stomatitis virus entry into host cells. Virology 338: 53–60.
29. Empfield JG, Goldsmith MA (2002) Association of the caveola vesicular system with cellular entry by filoviruses. J Virol 76: 5266–5270.
30. Pelkmans L, Kartenbeck J, Helenius A (2001) Caveolar endocytosis of simian virus 40 reveals a new two-step vesicular-transport pathway to the ER. Nat Cell Biol 3: 473–480.
31. Inoue Y, Tanaka N, Tanaka Y, Inoue S, Morita K, et al. (2007) Clathrin-dependent entry of severe acute respiratory syndrome coronavirus into target cells expressing ACE2 with the cytoplasmic tail deleted. J Virol 81: 6722–6729.
32. Smay D, Pinney E, Allard J (1994) Filipin-sensitive caveolae-mediated endocytosis in the infectious entry of human enterovirus 71. J Biol Chem 269: 4362–4370.
33. Richterova Z, Liebl D, Horko P, Volikova J, Kopecek J, et al. (2007) Caveola are involved in the trafficking of mouse polyomavirus virions and artificial VP1 pseudoparticles toward cell nuclei. J Virol 75: 10800–10810.
34. Conner SD, Schmid SL (2003) Regulated portals of entry into the cell. Nature 422: 47–54.
35. Marks B, Stowell MH, Vallis Y, Mills IG, Gibson A, et al. (2001) GTPase activity of dynamin and resulting conformation change are essential for endocytosis. Nature 410: 231–235.
36. Conner SD, Chang YH, Shin SJ, Kolesnick NM, Kolesnick RN, et al. (1995) Internalization of reovirus I in caveola. J Virol 70: 1856–1855.
37. Marks B, Stowell MH, Vallis Y, Mills IG, Gibson A, et al. (2001) GTPase activity of dynamin and resulting conformation change are essential for endocytosis. Nature 410: 231–235.
38. Altschuler Y, Barbas SM, Terlecky LJ, Tang K, Hardy S, et al. (1998) Caveolae mediate endocytosis during vesicular stomatitis virus entry into endothelial cells. Arch Biochem Biophys 373: 83–90.
39. Nawa M, Takasaki T, Yamada K, Kurane I, Akatsuka T, et al. (2003) Interference in cell-targeting of enterovirus 71 elicit immune response in mice. Genet Vaccines Ther 5: 6.
40. Soulet F, Yarar D, Leonard M, Schmid SL (2005) SNX9 regulates dynamin activity of dynamin and resulting conformation change are essential for endocytosis. Curr Opin Cell Biol 17: 1107–1117.
41. Eash S, Querbes W, Atwood WJ (2004) Interaction of enterovirus 71 using synthetic peptides. Virus Res 125: 61–68.
42. Mayor S, Pagano RE (2007) Pathways of clathrin-independent endocytosis. Nat Rev Mol Cell Biol 8: 603–612.
43. Nawa M, Takasaki T, Yamada K, Kurane I, Akatsuka T, et al. (2003) Interference in cell-targeting of enterovirus 71 elicit immune response in mice. Genet Vaccines Ther 5: 6.
44. Schnitzer JE, Oh P, Pinney E, Allard J (1994) Filipin-sensitive caveolae-mediated transport in endothelium: reduced trancytosis, scavenger endocytosis, and capillary permeability of select macromolecules. J Cell Biol 127: 1217–1232.
45. Baba T, Hamb WE, Iida K, Schmidt SL, et al. (1995) Role of dynamin in clathrin-coated vesicle formation. Cold Spring Harb Symp Quant Biol 60: 235–242.
46. Danthi P, Chow M (2004) Cholesterol removal by methyl-beta-cyclodextrin. Arch Biochem Biophys 373: 83–90.
47. Danthi P, Chow M (2004) Cholesterol removal by methyl-beta-cyclodextrin. Arch Biochem Biophys 373: 83–90.
48. Danthi P, Chow M (2004) Cholesterol removal by methyl-beta-cyclodextrin. Arch Biochem Biophys 373: 83–90.
49. Danthi P, Chow M (2004) Cholesterol removal by methyl-beta-cyclodextrin. Arch Biochem Biophys 373: 83–90.
50. Danthi P, Chow M (2004) Cholesterol removal by methyl-beta-cyclodextrin. Arch Biochem Biophys 373: 83–90.
51. Danthi P, Chow M (2004) Cholesterol removal by methyl-beta-cyclodextrin. Arch Biochem Biophys 373: 83–90.
52. Danthi P, Chow M (2004) Cholesterol removal by methyl-beta-cyclodextrin. Arch Biochem Biophys 373: 83–90.
53. Danthi P, Chow M (2004) Cholesterol removal by methyl-beta-cyclodextrin. Arch Biochem Biophys 373: 83–90.
54. Danthi P, Chow M (2004) Cholesterol removal by methyl-beta-cyclodextrin. Arch Biochem Biophys 373: 83–90.
55. Danthi P, Chow M (2004) Cholesterol removal by methyl-beta-cyclodextrin. Arch Biochem Biophys 373: 83–90.
56. Danthi P, Chow M (2004) Cholesterol removal by methyl-beta-cyclodextrin. Arch Biochem Biophys 373: 83–90.
57. Danthi P, Chow M (2004) Cholesterol removal by methyl-beta-cyclodextrin. Arch Biochem Biophys 373: 83–90.
58. Danthi P, Chow M (2004) Cholesterol removal by methyl-beta-cyclodextrin. Arch Biochem Biophys 373: 83–90.
59. Danthi P, Chow M (2004) Cholesterol removal by methyl-beta-cyclodextrin. Arch Biochem Biophys 373: 83–90.
